Abstract：Objective To explore the estimated value of serum cystatin C (CysC) for the risk stratification of non ST-elevation acute coronary syndrome (NSTE-ACS) patients with normal renal function. Methods Two hundred and eighty patients diagnosed as NSTE-ACS by coronary angiography in Affiliated Hospital of Xuzhou Medical University from January 2015 to December 2016 were selected as experimental group, 40 healthy subjects without NSTE-ACS diagnosed by coronary angiography were selected as control group. According to the scores of global registry of acute coronary events (GRACE), the experimental group was further divided into low risk group (≤108 points, 47 cases), moderate risk group (109-140 points, 106 cases) and high risk group (＞140 points, 127 cases). The differences of CysC between different groups and the correlation with GRACE score were explored, the independent predictive factors of GRACE scores were investigated, the estimated value of CysC for high risk of NSTE-ACS was analyzed by receiver operating characteristics (ROC), the independent predictive factors of high risk of NSTE-ACS were analyzed by Logistic multivariate regression analysis. Results The levels of CysC in experimental group were significantly higher than those of control group (P ＜ 0.05). The levels of CysC were positively correlated with GRACE scores (r = 0.561, P ＜ 0.05). The CysC is an independent predictive factor of GRACE score and high risk of NSTE-ACS (P ＜ 0.05). The ROC curve analysis showed that AUC was 0.788, P ＜ 0.05, the best cut-off point was 0.94, the sensitivity was 77%, the specificity was 72%. Conclusion The levels of CysC in NSTE-ACS patients with normal renal function are closely related to its risk stratification, which is the independent predictive factor of risk stratification and high risk of NSTE-ACS.
陈超 徐通达. 血清胱抑素C对肾功能正常的NSTE-ACS患者危险分层的评估价值[J]. 中国医药导报, 2017, 14(20): 70-73,100.
CHEN Chao XU Tongda. Estimated value of serum cystatin C for the risk stratification of non ST-elevation acute coronary syndrome patients with normal renal function. 中国医药导报, 2017, 14(20): 70-73,100.
[1] 中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）[J].中华心血管病杂志，2016，44（5）：382-400.
[2] Gevorgyan MM，Voronina NP，Goncharova NV，et al. Cystatin C as a Marker of Progressing Cardiovascular Events during Coronary Heart Disease [J]. Bull Exp Biol Med，2017， 162（4）：421-424.
[3] Sai E，Shimada K，Miyauchi K，et al. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents [J]. Heart Vessels，2016，31（5）：694-701.
[4] Goodman SG，Huang W，Yan AT，et al. The expanded Global Registry of Acute Coronary Events：baseline characteristics，management practices，and hospital outcomes of patients with acute coronary syndromes [J]. Am Heart J，2009， 158（2）：193-201.
[5] Do■aner Y ?覶，Aydo■an ?譈，Rohrer JE，et al. Comparison of estimated GFR equations based on serum cystatin C alone and in combination with serum creatinine in patients with coronary artery disease [J]. Anatol J Cardiol，2015，15（7）：72-80.
[6] Angelidis C，Deftereos S，Giannopoulos G，et al. Cystatin C：an emerging biomarker in cardiovascular disease [J]. Curr Top Med Chem，2013，13（2）：164-179.
[7] Joshi S，Viljoen A. Renal biomarkers for the prediction of cardiovascular disease [J]. Curr Opin Cardiol，2015，30（4）：454-460.
[8] Woitas RP，Kleber ME，Meinitzer A，et al. Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health（LURIC）study [J]. Atherosclerosis，2013，229（2）：541-548.
[9] Negruszkawecka M，Por?誰ba R，Hulok A． Evaluation of the significance of cystatin C levels in patients suffering from coronary artery disease [J]. Adv Clin Exp Med，2014，23（4）：551-558.
[10] Král A，Kovárník T，Vaní■ková Z，et al. Cystatin C Is Associated with the Extent and Characteristics of Coronary Atherosclerosis in Patients with Preserved Renal Function [J]. Folia Biologica，2016，62（6）：225-234.
[11] 薛国华，张守彦，马惠芳，等.非ST段抬高型急性冠状动脉综合征患者血清胱抑素C、高敏C反应蛋白水平与罪犯病变血管内超声显像特征的相关性[J].中国动脉硬化杂志，2016，24（12）：1248-1252.
[12] Wen Y，Xia D，Wang Y，et al. Cystatin C is Associated With Plaque Phenotype and Plaque Burden [J]. Kidney Blood Press Res，2016，41（2）：197-207.
[13] Damman P，van't Hof AW，Ten Berg JM，et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation：comments from the Dutch ACS working group [J]. Neth Heart J，2017，25（3）：181-185.
[14] Vieira C，Nabais S，Ramos V，et al. Multimarker approach with cystatin C，N-terminal pro-brain natriuretic peptide，C-reactive protein and red blood cell distribution width in risk stratification of patients with acute coronary syndromes [J]. Rev Port Cardiol，2014，33（3）：127-136.
[15] Flores-Blanco PJ，López-Cuenca ?譧，Januzzi JL，et al. Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Non-ST-Segment Elevation Acute Coronary Syndrome [J]. Clin Cardiol，2016，39（9）：507-515.
[16] Lee M，Saver JL，Huang WH，et al. Impact of elevated cystatin C level on cardiovascular disease risk inpredominantly high cardiovascular risk populations：a meta-analysis [J]. Circ Cardiovasc Qual Outcomes，2010，3（6）：675-683.
[17] Luo J，Wang LP，Hu HF，et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population：A meta-analysis [J]. Clin Chim Acta，2015，450（10）：39-45.
[18] Silva D，Cortez-Dias N，Jorge C，et al. Cystatin C as Prognostic Biomarker in ST-Segment Elevation Acute Myocardial Infarction [J]. Am J Cardiol，2012，109（10）：1431-1438.
[19] Windhausen F，Hirsch A，Fischer J，et al. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T [J]. Clin Chem，2009，55（6）：1118-1125.
[20] Bassand JP，Hamm CW，Ardissino D，et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes [J]. Eur Heart J，2008， 28（2）：1598-1660.
2017, Vol. 14 
京公网安备 11010502046598号